Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jointanork is a multi-ingredient dietary supplement developed by ARAX Pharmaceutical Industries for joint health and musculoskeletal support. It contains a combination of hyaluronic acid, collagen hydrolysate, glucosamine sulfate, methylsulfonylmethane (MSM), and chondroitin sulfate. These components work synergistically to maintain joint integrity; hyaluronic acid provides lubrication and cushioning within the synovial fluid, while collagen, glucosamine, and chondroitin serve as structural building blocks for cartilage and connective tissues. MSM provides organic sulfur, which is essential for collagen synthesis and has anti-inflammatory properties. It is marketed as an affordable health product in Egypt, typically formulated as an orange-flavored powder or oral supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jointanork.